Tube Formation Bioassay: A Versatile Tool for Studying Angiogenesis
Angiogenesis is the process of forming new blood vessels from pre-existing ones. It is essential for growth and development, wound healing, and tissue regeneration. However, angiogenesis can also play a role in pathological conditions such as cancer, diabetic retinopathy, and macular degeneration.
The tube formation bioassay is a widely used in vitro assay to assess angiogenesis. It measures the ability of endothelial cells to form capillary-like structures on a basement membrane matrix. The assay is relatively simple to perform and can be used to screen for inhibitors and stimulators of angiogenesis, as well as to study the underlying mechanisms of angiogenesis.
Therapeutic Relevance
Many factors of the extracellular matrix affect the formation of angiogenesis, particularly vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMP-1, MMP-2, MMP-9), angiopoietin-1 and 2. Other factors that affect capillary formation include cytokines and chemokines like the growth-regulated oncogene-α (GRO-α), Monocyte chemotactic protein-1 (MCP-1/CCL-2), interleukin -1β (IL-1β), tissue necrosis factor-α (TNF-α), thrombin and more.
Bevacizumab (anti-VEGF) was the first anti-angiogenesis drug approved by FDA for colorectal cancer. Since then inhibition of angiogenesis became a target in many cancers including breast, prostate, ovarian, lung, glioma and more. Other diseases that anti-angiogenesis and pro-angiogenesis therapeutics play important role include, arteriosclerosis, myocardial infarction, ulcer, limb ischemia, tissue ischemia, retinopathies and diabetes. In many of these disorders and diseases angiogenesis therapy addresses tissue repair to reverse or inhibit the disease progress.
Bevacizumab
Bevacizumab is a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), a key regulator of angiogenesis. Bevacizumab is approved for the treatment of a variety of cancers, including colorectal cancer, non-small cell lung cancer, and metastatic breast cancer. Bevacizumab works by blocking the binding of VEGF to its receptors on endothelial cells, thereby inhibiting angiogenesis and tumor growth.
Tube Formation Bioassay to Study Bevacizumab
The tube formation bioassay can be used to study the effects of bevacizumab on angiogenesis. For example, endothelial cells can be treated with different concentrations of bevacizumab and then assessed for their ability to form capillary-like structures. The results can be used to determine the dose of bevacizumab required to inhibit angiogenesis by 50% (IC50).
The tube formation bioassay can also be used to study the mechanisms by which bevacizumab inhibits angiogenesis. For example, endothelial cells can be treated with bevacizumab and then assessed for changes in the expression of genes and proteins involved in angiogenesis. The results can be used to identify new targets for therapeutic intervention.
Examples of Tube Formation Bioassay Studies on Bevacizumab
Additional Applications of the Tube Formation Bioassay
The tube formation bioassay can also be used to study the effects of other factors on angiogenesis, such as:
The tube formation bioassay is a powerful tool for studying the complex process of angiogenesis and the effects of bevacizumab on angiogenesis. It can be used to screen for inhibitors of angiogenesis, study the mechanisms by which bevacizumab inhibits angiogenesis, and evaluate the efficacy of combination therapy with bevacizumab and other anti-angiogenic agents.
Please contact SBH with your specific needs or any questions related to Tube Formation Bioassay.